Our approach combines precision immunology and T-cell engineering to create therapies that detect and eliminate ALK-driven tumors with unmatched specificity—offering new hope where resistance has taken hold.
Shaping a future where ALK+ cancers no longer dictate the outcome.
ALKemist Bio has appointed Dr. Markus Dangl as Chief Executive Officer and member of its Board of Directors. Bringing more than 25 years of experience in oncology and immunology drug development, he will lead the company's next phase of growth, advancing its ALK-positive cancer pipeline and preparing for a Series A financing round to accelerate the development of new treatment options for patients.
ALKemist Bio has appointed Dr. Adi Hoess as an independent Board member. With over 30 years of leadership in immuno-oncology and cell therapies, Dr. Hoess brings valuable expertise as the company advances its ALK-specific T cell therapies toward clinical development. His experience, including a 13-year tenure as CEO of Affimed, will support ALKemist’s mission to improve outcomes for patients with aggressive ALK-positive cancers.
ALKemist Bio signs exclusive license with Boston Children’s Hospital and launches a 2-year research deal to develop TCR therapies for ALK-positive tumors, advancing novel cancer treatments from Prof. Chiarle’s groundbreaking research.
ALKemist Bio, biotech startup from Turin, raises €6.9M to develop first-in-class TCR cell therapies targeting ALK-positive tumors, based on research by Prof. Roberto Chiarle, aiming to offer innovative treatments for aggressive cancers.
